Stay updated with breaking news from Code Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 ...
HC Wainwright reaffirmed their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock. TransCode Therapeutics Stock Performance RNAZ stock opened at $1.15 on Thursday. The stock’s 50 day moving average price is […]
Cogent Biosciences (NASDAQ:COGT – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Analyst Ratings This is a breakdown of […]
See which leaders are on the move across the pharma, biotech and medical marketing industries.